

Influenza Diagnostics Market by Product (Test Kits, Instruments), Test Type (Traditional (RIDT, Viral Culture, Serological), Molecular (PCR, INAAT-NASBAT, TMABAS)), End User (Diagnostic Laboratories, Hospitals, Clinics), Region-Global Forecast to 2026

<https://marketpublishers.com/r/I3116886C7EEN.html>

Date: September 2021

Pages: 188

Price: US\$ 4,950.00 (Single User License)

ID: I3116886C7EEN

Abstracts

The global influenza diagnostics market is projected to reach USD 1.1 billion by 2026 from USD 0.8 billion in 2021, at a CAGR of 7.7% during the forecast period. Market growth is driven by factors such as the growth in influenza research for diagnostic technologies, rising demand for rapid disease diagnosis and increasing prevalence of influenza. On the other hand, rising healthcare costs, variabilities in test sensitivity and specificity are the major factors hampering the growth of this market.

“The test kits and reagents segment accounted for the highest growth rate in the influenza diagnostics market, by product, during the forecast period”

The influenza diagnostics market is segmented into test kits and reagents, instruments and other products based on product. In 2020, the test kits and reagents segment accounted for the highest growth rate in the influenza diagnostics market. Increasing prevalence of influenza and rising demand for rapid disease diagnosis are major factors contributing to the growth of this segment.

“The molecular diagnostic tests segment accounted for the highest growth rate in the influenza diagnostics market, by test type, during the forecast period”

The influenza diagnostics market is segmented into molecular diagnostic tests and

traditional diagnostic tests based on test type. In 2020, the molecular diagnostic tests segment accounted for the highest growth rate in the influenza diagnostics market. Growth in influenza research for diagnostic technologies and rising demand for rapid disease diagnosis are major factor contributing to the growth of this segment.

“Diagnostic laboratories segment accounted for the highest CAGR”

Based on end user, the influenza diagnostics market is segmented into diagnostic laboratories, hospitals and clinics and other end users. In 2020, the hospitals and clinics segment accounted for the highest CAGR. This can be attributed to the rising demand for rapid disease diagnosis and increasing prevalence of influenza.

“Asia Pacific: The fastest-growing region in influenza diagnostics market”

The global influenza diagnostics market is segmented into North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Factors such as the rising demand for rapid disease diagnosis and growth in influenza research for diagnostic technologies are driving the growth of the influenza diagnostics market in this region.

The primary interviews conducted for this report can be categorized as follows:

By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%

By Designation: C-level - 27%, D-level - 18%, and Others - 55%

By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and the Middle East & Africa – 4%

Lists of Companies Profiled in the Report:

Danaher Corporation (US)

Siemens Healthineers (Germany)

Thermo Fisher Scientific, Inc. (US)

F. Hoffmann-LA Roche AG (Switzerland)

Abbott Laboratories, Inc. (Us)

Hologic, Inc. (US)

bioMérieux SA (France)

Quidel Corporation (US)

Becton, Dickinson and Company (US)

Meridian Bioscience (US)

GenMark Diagnostics, Inc. (US)

Luminex Corporation (US)

Tecan Trading AG (Switzerland)

DiaSorin SA (Italy)

altona Diagnostics GmbH (Germany)

SEKISUI Diagnostics (US)

SA Scientific Ltd. (US)

CorisBioConcept SPRL (Belgium)

ELITech Group (France)

Mast Group Ltd. (UK)

Genome Diagnostics, Pvt. Ltd. (India)

Germaine Laboratories, Inc. (US)

Response Biomedical Corp. (Canada)

Tauns Laboratories, Inc. (Japan)

3B BlackBio Biotech India Ltd. (India)

Research Coverage:

This report provides a detailed picture of the global influenza diagnostics market. It aims at estimating the size and future growth potential of the market across different segments, such as product, test type, end user and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall influenza diagnostics market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

Contents

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY

1.2.2 MARKETS COVERED

FIGURE 1 INFLUENZA DIAGNOSTICS MARKET SEGMENTATION

1.2.3 YEARS CONSIDERED FOR THE STUDY

1.3 CURRENCY

1.4 LIMITATIONS

1.5 STAKEHOLDERS

1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA

2.2 RESEARCH APPROACH

FIGURE 2 INFLUENZA DIAGNOSTICS MARKET: RESEARCH DESIGN

2.2.1 SECONDARY DATA

2.2.1.1 Key data from secondary sources

2.2.2 PRIMARY DATA

2.2.2.1 Key data from primary sources

2.2.2.2 Key industry insights

FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION

2.3 MARKET SIZE ESTIMATION

2.3.1 BOTTOM-UP APPROACH

FIGURE 4 INFLUENZA DIAGNOSTICS MARKET: BOTTOM-UP APPROACH

FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS

2.3.2 TOP-DOWN APPROACH

FIGURE 6 INFLUENZA DIAGNOSTICS MARKET: TOP-DOWN APPROACH

2.4 MARKET BREAKDOWN & DATA TRIANGULATION

FIGURE 7 DATA TRIANGULATION METHODOLOGY

2.5 ASSUMPTIONS FOR THE STUDY

2.6 GROWTH RATE ASSUMPTIONS

2.7 LIMITATIONS

2.8 RISK ASSESSMENT

2.9 COVID-19 HEALTH ASSESSMENT

2.10 COVID-19 ECONOMIC ASSESSMENT

2.11 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO

FIGURE 8 CRITERIA IMPACTING THE GLOBAL ECONOMY

FIGURE 9 RECOVERY SCENARIO OF THE GLOBAL ECONOMY

2.12 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE INFLUENZA

DIAGNOSTICS MARKET

3 EXECUTIVE SUMMARY

FIGURE 10 INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2021 VS. 2026
(USD MILLION)

FIGURE 11 INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2021 VS. 2026
(USD MILLION)

FIGURE 12 INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2021 VS. 2026
(USD MILLION)

FIGURE 13 INFLUENZA DIAGNOSTICS MARKET, BY REGION, 2021 VS. 2026 (USD
MILLION)

4 PREMIUM INSIGHTS

4.1 INFLUENZA DIAGNOSTICS MARKET OVERVIEW

FIGURE 14 INCREASING PREVALENCE OF INFLUENZA TO DRIVE MARKET
GROWTH

4.2 INFLUENZA DIAGNOSTICS MARKET SHARE, BY PRODUCT, 2021 VS. 2026
FIGURE 15 TEST KITS & REAGENTS WILL CONTINUE TO DOMINATE THE
MARKET IN 2026

4.3 INFLUENZA DIAGNOSTICS MARKET SHARE, BY TEST TYPE, 2021 VS. 2026
FIGURE 16 MOLECULAR DIAGNOSTIC TESTS TO DOMINATE THE MARKET
DURING THE FORECAST PERIOD

4.4 INFLUENZA DIAGNOSTICS MARKET SHARE, BY END USER, 2021 VS. 2026
FIGURE 17 DIAGNOSTIC LABORATORIES ARE THE LARGEST END USERS OF
THE INFLUENZA DIAGNOSTICS MARKET

4.5 INFLUENZA DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH
OPPORTUNITIES

FIGURE 18 NORTH AMERICA TO COMMAND THE LARGEST SHARE AND ASIA
PACIFIC TO REGISTER THE HIGHEST GROWTH RATE IN THE INFLUENZA
DIAGNOSTICS MARKET DURING THE FORECAST PERIOD

5 MARKET OVERVIEW

5.1 INTRODUCTION

5.2 MARKET DYNAMICS

FIGURE 19 INFLUENZA DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES

5.2.1 DRIVERS

5.2.1.1 Increasing prevalence of influenza

5.2.1.2 Growth in influenza research for diagnostic technologies

5.2.1.3 Rising demand for rapid disease diagnosis

5.2.2 RESTRAINTS

5.2.2.1 Variabilities in test sensitivity and specificity

5.2.2.2 Rising healthcare costs

5.2.3 OPPORTUNITIES

5.2.3.1 Advancements in genomic and proteomic technologies

5.2.3.2 Significant growth prospects in developing countries

5.2.4 CHALLENGES

5.2.4.1 Lack of skilled professionals

5.2.4.2 Stringent regulatory frameworks

5.3 IMPACT OF COVID-19 ON THE INFLUENZA DIAGNOSTICS MARKET

5.4 PRICING ANALYSIS

TABLE 1 PRICES OF INFLUENZA DIAGNOSTIC PRODUCTS (2021)

5.5 PATENT ANALYSIS

5.6 TRADE ANALYSIS

5.6.1 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS

TABLE 2 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2016–2020 (USD MILLION)

TABLE 3 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2016–2020 (USD MILLION)

5.7 VALUE CHAIN ANALYSIS

FIGURE 20 MAJOR VALUE IS ADDED DURING THE MANUFACTURING & ASSEMBLY PHASES

5.8 SUPPLY CHAIN ANALYSIS

FIGURE 21 DISTRIBUTION—A STRATEGY PREFERRED BY PROMINENT COMPANIES

5.9 ECOSYSTEM ANALYSIS OF THE INFLUENZA DIAGNOSTICS MARKET

FIGURE 22 INFLUENZA DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS

5.9.1 ROLE IN THE ECOSYSTEM

5.10 PORTER'S FIVE FORCES ANALYSIS

TABLE 4 INFLUENZA DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS

- 5.10.1 THREAT FROM NEW ENTRANTS
- 5.10.2 THREAT FROM SUBSTITUTES
- 5.10.3 BARGAINING POWER OF BUYERS
- 5.10.4 BARGAINING POWER OF SUPPLIERS
- 5.10.5 DEGREE OF COMPETITION

5.11 PESTLE ANALYSIS**5.12 REGULATORY LANDSCAPE****5.12.1 NORTH AMERICA**

- 5.12.1.1 US
- 5.12.1.2 Canada

5.12.2 EUROPE**5.12.3 ASIA PACIFIC**

- 5.12.3.1 Japan
- 5.12.3.2 India
- 5.12.3.3 China

5.12.4 LATIN AMERICA

- 5.12.4.1 Brazil
- 5.12.4.2 Mexico

5.12.5 MIDDLE EAST**5.12.6 AFRICA****5.13 TECHNOLOGY ANALYSIS****5.14 DISRUPTIVE TECHNOLOGIES IN THE INFLUENZA DIAGNOSTICS MARKET****5.14.1 REVENUE SHIFT & REVENUE POCKETS FOR THE INFLUENZA DIAGNOSTICS MARKET****FIGURE 23 REVENUE SHIFT FOR THE INFLUENZA DIAGNOSTICS MARKET****6 INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT****6.1 INTRODUCTION****TABLE 5 INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)****6.2 TEST KITS & REAGENTS****6.2.1 REPEAT PURCHASE OF TEST KITS & REAGENTS TO DRIVE MARKET GROWTH IN THE COMING YEARS****FIGURE 24 INSIGHTS FROM INDUSTRY EXPERTS ON TEST KITS & REAGENTS****TABLE 6 INFLUENZA DIAGNOSTICS MARKET FOR TEST KITS & REAGENTS, BY REGION, 2019–2026 (USD MILLION)**

6.3 INSTRUMENTS

6.3.1 INCREASING NEED FOR FASTER & MORE ACCURATE TEST RESULTS TO PROPEL MARKET GROWTH

TABLE 7 KEY INSTRUMENTS IN THE INFLUENZA DIAGNOSTICS MARKET

TABLE 8 INFLUENZA DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2019–2026 (USD MILLION)

6.4 OTHER PRODUCTS

TABLE 9 INFLUENZA DIAGNOSTICS MARKET FOR OTHER PRODUCTS, BY REGION, 2019–2026 (USD MILLION)

7 INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE

7.1 INTRODUCTION

TABLE 10 INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)

7.2 MOLECULAR DIAGNOSTIC TESTS

TABLE 11 MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 12 MOLECULAR DIAGNOSTIC TESTS MARKET, BY REGION, 2019–2026 (USD MILLION)

7.2.1 POLYMERASE CHAIN REACTION TESTS

7.2.1.1 Ability of PCR tests to distinguish between influenza A and B viruses is driving its adoption in clinical settings

TABLE 13 POLYMERASE CHAIN REACTION TESTS MARKET, BY REGION, 2019–2026 (USD MILLION)

7.2.2 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS

TABLE 14 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 15 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY REGION, 2019–2026 (USD MILLION)

7.2.2.1 Transcription-mediated amplification-based assays

7.2.2.1.1 Wide application range in pathogen detection to drive the market growth
TABLE 16 TRANSCRIPTION-MEDIATED AMPLIFICATION-BASED ASSAYS MARKET, BY REGION, 2019–2026 (USD MILLION)

7.2.2.2 Loop-mediated isothermal amplification-based assays

7.2.2.2.1 Rapidity, stability, and sensitivity have driven the use of loop-mediated isothermal amplification-based assays

TABLE 17 LOOP-MEDIATED ISOTHERMAL AMPLIFICATION-BASED ASSAYS MARKET, BY REGION, 2019–2026 (USD MILLION)

7.2.2.3 Nucleic acid sequence-based amplification assays

7.2.2.3.1 Nucleic acid sequence-based amplification assays are preferred in hospitals and clinical settings as they reduce the need for additional reverse transcription steps

TABLE 18 NUCLEIC ACID SEQUENCE-BASED AMPLIFICATION ASSAYS MARKET, BY REGION, 2019–2026 (USD MILLION)

7.2.2.4 Other isothermal nucleic acid amplification tests

TABLE 19 OTHER ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY REGION, 2019–2026 (USD MILLION)

7.2.3 OTHER MOLECULAR DIAGNOSTIC TESTS

TABLE 20 OTHER MOLECULAR DIAGNOSTIC TESTS MARKET, BY REGION, 2019–2026 (USD MILLION)

7.3 TRADITIONAL DIAGNOSTIC TESTS

TABLE 21 TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 22 TRADITIONAL DIAGNOSTIC TESTS MARKET, BY REGION, 2019–2026 (USD MILLION)

7.3.1 RAPID INFLUENZA DIAGNOSTIC TESTS

7.3.1.1 Rapid influenza diagnostic tests are widely used due to their ease of use and rapid interpretability of results

TABLE 23 RAPID INFLUENZA DIAGNOSTIC TESTS MARKET, BY REGION, 2019–2026 (USD MILLION)

7.3.2 VIRAL CULTURE TESTS

7.3.2.1 Wide use of viral cultures as confirmatory tests to ensure the results of RIDTs to drive market growth

TABLE 24 VIRAL CULTURE TESTS MARKET, BY REGION, 2019–2026 (USD MILLION)

7.3.3 DIRECT FLUORESCENT ANTIBODY TESTS

7.3.3.1 Adoption of DFA tests is increasing due to their higher sensitivity compared to RIDTs

TABLE 25 DIRECT FLUORESCENT ANTIBODY TESTS MARKET, BY REGION, 2019–2026 (USD MILLION)

7.3.4 SEROLOGICAL TESTS

7.3.4.1 Development of lab-on-chip-based multiplex assays to support market growth

TABLE 26 SEROLOGICAL TESTS MARKET, BY REGION, 2019–2026 (USD MILLION)

8 INFLUENZA DIAGNOSTICS MARKET, BY END USER

8.1 INTRODUCTION

TABLE 27 INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)

8.2 DIAGNOSTIC LABORATORIES

8.2.1 LARGE NUMBER OF INFLUENZA DIAGNOSTIC TESTS PERFORMED IN DIAGNOSTIC LABORATORIES TO DRIVE MARKET GROWTH

TABLE 28 INFLUENZA DIAGNOSTICS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2019–2026 (USD MILLION)

8.3 HOSPITALS & CLINICS

8.3.1 GROWING GLOBAL NUMBER OF HOSPITALS DUE TO INCREASING INFECTIOUS DISEASE INCIDENCE TO DRIVE MARKET GROWTH

TABLE 29 INFLUENZA DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS, BY REGION, 2019–2026 (USD MILLION)

8.4 OTHER END USERS

TABLE 30 INFLUENZA DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2019–2026 (USD MILLION)

9 INFLUENZA DIAGNOSTICS MARKET, BY REGION

9.1 INTRODUCTION

TABLE 31 INFLUENZA DIAGNOSTICS MARKET, BY REGION, 2019–2026 (USD MILLION)

TABLE 32 INFLUENZA DIAGNOSTICS MARKET, BY REGION, 2019–2026 (MILLION TESTS)

9.2 NORTH AMERICA

FIGURE 25 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET SNAPSHOT

TABLE 33 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

TABLE 34 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 35 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)

TABLE 36 NORTH AMERICA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 37 NORTH AMERICA: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 38 NORTH AMERICA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 39 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)

9.2.1 US

9.2.1.1 Technological advancements in influenza diagnostics to favor market growth in the US

TABLE 40 US: PRODUCT APPROVALS IN THE INFLUENZA DIAGNOSTICS MARKET

TABLE 41 US: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 42 US: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)

TABLE 43 US: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 44 US: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 45 US: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 46 US: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)

9.2.2 CANADA

9.2.2.1 Government initiatives for developing diagnostic techniques to support market growth in Canada

TABLE 47 CANADA: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 48 CANADA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)

TABLE 49 CANADA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 50 CANADA: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 51 CANADA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 52 CANADA: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)

9.3 EUROPE

TABLE 53 EUROPE: INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

TABLE 54 EUROPE: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 55 EUROPE: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)

TABLE 56 EUROPE: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 57 EUROPE: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 58 EUROPE: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 59 EUROPE: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)

9.3.1 GERMANY

9.3.1.1 Increasing demand for technologically advanced diagnostic techniques to drive market growth in Germany

TABLE 60 GERMANY: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 61 GERMANY: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)

TABLE 62 GERMANY: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 63 GERMANY: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 64 GERMANY: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 65 GERMANY: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)

9.3.2 ITALY

9.3.2.1 Well-developed healthcare system in Italy to drive the adoption of advanced diagnostic technologies

TABLE 66 ITALY: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 67 ITALY: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)

TABLE 68 ITALY: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 69 ITALY: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 70 ITALY: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 71 ITALY: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)

9.3.3 FRANCE

9.3.3.1 High healthcare expenditure by the government to drive market growth in France

TABLE 72 FRANCE: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 73 FRANCE: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)

TABLE 74 FRANCE: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 75 FRANCE: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 76 FRANCE: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 77 FRANCE: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)

9.3.4 SPAIN

9.3.4.1 Healthcare infrastructural improvements indicate favorable prospects for market growth in Spain

TABLE 78 SPAIN: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 79 SPAIN: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)

TABLE 80 SPAIN: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 81 SPAIN: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 82 SPAIN: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 83 SPAIN: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)

9.3.5 UK

9.3.5.1 Frequent influenza outbreaks in the UK to boost the growth of the influenza diagnostics market

TABLE 84 UK: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 85 UK: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)

TABLE 86 UK: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 87 UK: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY

TYPE, 2019–2026 (USD MILLION)

TABLE 88 UK: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 89 UK: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)

9.3.6 REST OF EUROPE

TABLE 90 ROE: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 91 ROE: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)

TABLE 92 ROE: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 93 ROE: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 94 ROE: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 95 ROE: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)

9.4 ASIA PACIFIC

FIGURE 26 ASIA PACIFIC: INFLUENZA DIAGNOSTICS MARKET SNAPSHOT

TABLE 96 ASIA PACIFIC: INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

TABLE 97 ASIA PACIFIC: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 98 ASIA PACIFIC: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)

TABLE 99 ASIA PACIFIC: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 100 ASIA PACIFIC: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 101 ASIA PACIFIC: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 102 ASIA PACIFIC: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)

9.4.1 CHINA

9.4.1.1 Growing investments by government agencies to drive market growth in China

TABLE 103 CHINA: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 104 CHINA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)

TABLE 105 CHINA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 106 CHINA: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 107 CHINA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 108 CHINA: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)

9.4.2 JAPAN

9.4.2.1 Universal healthcare reimbursement policy to drive market growth in Japan

TABLE 109 JAPAN: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 110 JAPAN: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)

TABLE 111 JAPAN: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 112 JAPAN: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 113 JAPAN: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 114 JAPAN: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)

9.4.3 INDIA

9.4.3.1 Increase in public and private investments in the country's healthcare system will drive market growth

TABLE 115 INDIA: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 116 INDIA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)

TABLE 117 INDIA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 118 INDIA: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 119 INDIA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 120 INDIA: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)

9.4.4 REST OF ASIA PACIFIC

TABLE 121 ROAPAC: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 122 ROAPAC: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)

TABLE 123 ROAPAC: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 124 ROAPAC: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 125 ROAPAC: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 126 ROAPAC: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)

9.5 LATIN AMERICA

9.5.1 RISING DISEASE PREVALENCE AND INCREASING HEALTHCARE EXPENDITURE TO DRIVE THE LATAM MARKET

TABLE 127 LATIN AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 128 LATIN AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)

TABLE 129 LATIN AMERICA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 130 LATIN AMERICA: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 131 LATIN AMERICA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 132 LATIN AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)

9.6 MIDDLE EAST & AFRICA

9.6.1 RISING ACCESS TO ADVANCED TECHNOLOGIES AND GROWING INVESTMENTS WILL SUPPORT MARKET GROWTH

TABLE 133 MIDDLE EAST & AFRICA: INFLUENZA DIAGNOSTICS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)

TABLE 134 MIDDLE EAST & AFRICA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2019–2026 (USD MILLION)

TABLE 135 MIDDLE EAST & AFRICA: MOLECULAR DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 136 MIDDLE EAST & AFRICA: ISOTHERMAL NUCLEIC ACID AMPLIFICATION TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 137 MIDDLE EAST & AFRICA: TRADITIONAL DIAGNOSTIC TESTS MARKET, BY TYPE, 2019–2026 (USD MILLION)

TABLE 138 MIDDLE EAST & AFRICA: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2019–2026 (USD MILLION)

10 COMPETITIVE LANDSCAPE

10.1 OVERVIEW

10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN

10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE INFLUENZA DIAGNOSTICS MARKET

TABLE 139 STRATEGIES ADOPTED BY KEY INFLUENZA DIAGNOSTIC PRODUCT MANUFACTURING COMPANIES

10.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS

FIGURE 27 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE INFLUENZA DIAGNOSTICS MARKET

10.4 MARKET SHARE ANALYSIS

FIGURE 28 INFLUENZA DIAGNOSTICS MARKET SHARE, BY KEY PLAYER (2020)

TABLE 140 INFLUENZA DIAGNOSTICS MARKET: DEGREE OF COMPETITION

10.5 COMPANY EVALUATION QUADRANT

10.5.1 STARS

10.5.2 EMERGING LEADERS

10.5.3 PERVASIVE PLAYERS

10.5.4 PARTICIPANTS

FIGURE 29 INFLUENZA DIAGNOSTICS MARKET: COMPANY EVALUATION QUADRANT, 2020

10.6 COMPANY EVALUATION QUADRANT FOR STARTUPS/SMES (2020)

10.6.1 PROGRESSIVE COMPANIES

10.6.2 STARTING BLOCKS

10.6.3 RESPONSIVE COMPANIES

10.6.4 DYNAMIC COMPANIES

FIGURE 30 INFLUENZA DIAGNOSTICS MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2020

10.7 COMPETITIVE BENCHMARKING

FIGURE 31 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF THE TOP PLAYERS IN THE INFLUENZA DIAGNOSTICS MARKET

TABLE 141 COMPANY PRODUCT FOOTPRINT

TABLE 142 COMPANY REGIONAL FOOTPRINT

10.8 COMPETITIVE SCENARIO

10.8.1 PRODUCT LAUNCHES & APPROVALS

TABLE 143 KEY PRODUCT LAUNCHES & APPROVALS

10.8.2 DEALS

TABLE 144 KEY DEALS

11 COMPANY PROFILES

11.1 KEY PLAYERS

(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*

11.1.1 THERMO FISHER SCIENTIFIC, INC.

TABLE 145 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW

FIGURE 32 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2020)

11.1.2 BECTON, DICKINSON AND COMPANY

TABLE 146 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW

FIGURE 33 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020)

11.1.3 F. HOFFMANN-LA ROCHE AG

TABLE 147 F. HOFFMANN-LA ROCHE AG: BUSINESS OVERVIEW

FIGURE 34 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2020)

11.1.4 HOLOGIC, INC.

TABLE 148 HOLOGIC, INC.: BUSINESS OVERVIEW

FIGURE 35 HOLOGIC, INC.: COMPANY SNAPSHOT (2020)

11.1.5 ABBOTT LABORATORIES, INC.

TABLE 149 ABBOTT LABORATORIES, INC.: BUSINESS OVERVIEW

FIGURE 36 ABBOTT LABORATORIES, INC.: COMPANY SNAPSHOT (2020)

11.1.6 DANAHER CORPORATION

TABLE 150 DANAHER CORPORATION: BUSINESS OVERVIEW

FIGURE 37 DANAHER CORPORATION: COMPANY SNAPSHOT (2020)

11.1.7 QUIDEL CORPORATION

TABLE 151 QUIDEL CORPORATION: BUSINESS OVERVIEW

FIGURE 38 QUIDEL CORPORATION: COMPANY SNAPSHOT (2020)

11.1.8 SIEMENS HEALTHINEERS

TABLE 152 SIEMENS HEALTHINEERS: BUSINESS OVERVIEW

FIGURE 39 SIEMENS HEALTHINEERS: COMPANY SNAPSHOT (2020)

11.1.9 BIOM?RIEUX SA

TABLE 153 BIOM?RIEUX SA: BUSINESS OVERVIEW

FIGURE 40 BIOM?RIEUX SA: COMPANY SNAPSHOT (2020)

11.1.10 MERIDIAN BIOSCIENCE

TABLE 154 MERIDIAN BIOSCIENCE: BUSINESS OVERVIEW
FIGURE 41 MERIDIAN BIOSCIENCE: COMPANY SNAPSHOT (2020)

11.2 OTHER PLAYERS

- 11.2.1 GENMARK DIAGNOSTICS, INC.
- 11.2.2 LUMINEX CORPORATION
- 11.2.3 TECAN TRADING AG
- 11.2.4 DIASORIN SA
- 11.2.5 ALTONA DIAGNOSTICS GMBH
- 11.2.6 SEKISUI DIAGNOSTICS
- 11.2.7 SA SCIENTIFIC, LTD.
- 11.2.8 CORIS BIOCONCEPT SPRL
- 11.2.9 ELITECH GROUP
- 11.2.10 MAST GROUP LTD.
- 11.2.11 GENOME DIAGNOSTICS PVT. LTD.
- 11.2.12 GERMAINE LABORATORIES, INC.
- 11.2.13 RESPONSE BIOMEDICAL CORP.
- 11.2.14 TAUNS LABORATORIES, INC.
- 11.2.15 3B BLACKBIO BIOTECH INDIA LTD.

*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

12 APPENDIX

- 12.1 INSIGHTS FROM INDUSTRY EXPERTS
- 12.2 DISCUSSION GUIDE
- 12.3 KNOWLEDGE STORE: MARKETSandMARKETS' SUBSCRIPTION PORTAL
- 12.4 AVAILABLE CUSTOMIZATIONS
- 12.5 RELATED REPORTS
- 12.6 AUTHOR DETAILS

I would like to order

Product name: Influenza Diagnostics Market by Product (Test Kits, Instruments), Test Type (Traditional (RIDT, Viral Culture, Serological), Molecular (PCR, INAAT- NASBAT, TMABAS)), End User (Diagnostic Laboratories, Hospitals, Clinics), Region-Global Forecast to 2026

Product link: <https://marketpublishers.com/r/I3116886C7EEN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/I3116886C7EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970